皮肤T细胞淋巴瘤异基因造血细胞移植:EBMT PH&G委员会推荐
该共识指南由EBMT PH&G委员会基于文献综述与皮肤科、血液科专家讨论制定,针对蕈样肉芽肿(MF)和Sézary综合征(SS)的异基因造血细胞移植(allo-HCT)提出推荐。内容涵盖患者选择、时机、桥接治疗、供者来源、预处理方案及移植后管理,强调对高危患者应早期考虑allo-HCT并与移植血液科医生并行会诊和供者搜索。
要点
- 高危MF/SS患者应早期考虑allo-HCT,包括晚期、大细胞转化、系统治疗后复发/难治及N3期淋巴结受累。
- 上述指征应触发与移植血液科医生会诊,同时启动供者搜索。
- 皮肤科与移植血液科早期互动至关重要,可避免延误并改善移植后结局和生存。
核心结论
- 对符合条件的高危MF/SS患者,应在疾病管理早期考虑allo-HCT。
- 晚期、大细胞转化、系统治疗后复发或难治、N3期淋巴结受累是指征,应触发移植血液科会诊并同步供者搜索。
- 皮肤科与移植血液科早期互动可避免延误,从而可能改善移植后结局和生存。
研究设计与样本
- 该共识指南基于全面文献综述及顶尖皮肤科与血液科专家讨论制定。
关键数值与推荐
- 晚期、大细胞转化、系统治疗后复发或难治、N3期淋巴结受累为应触发移植血液科会诊的指征。
临床怎么用
- 对具有上述高危指征的MF/SS患者,应早期转诊移植血液科并同步启动供者搜索。
- 皮肤科医生应与移植血液科医生早期协作,避免移植延迟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists. These recommendations aim to harmonize clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo-HCT early in the management of eligible patients with high-risk disease. Advanced stage, large-cell transformation, relapsed or refractory disease following systemic treatment, and N3-stage lymph node involvement are indicators that should trigger consultation with a transplant haematologist in parallel with a donor search. Early interaction between dermatologists and transplant haematologists is vital to avoiding delays, which can significantly impact post-transplant outcomes and survival.
引用
- Damaj G, de Masson A, Dreger P, et al. Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee. J Eur Acad Dermatol Venereol. 2025. PMID: 41031482. doi:10.1111/jdv.70042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。